+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07426757

Open-Label Study Evaluating Oral PF-07994525 in Participants With Advanced Malignancies Including Multiple Myeloma

Led by Pfizer · Updated on 2026-10-13

120

Participants Needed

26

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating PF-07994525 in participants with relapsed or refractory multiple myeloma RR MM to study its safety, tolerability, how the body processes the drug pharmacokinetics, its effects on the body pharmacodynamics, and its potential antitumor activity. This open-label Phase 1 trial includes a dose escalation phase to find a safe dose and a dose expansion phase to further assess the treatment in more participants with advanced cancers. Participants will receive PF-07994525 orally in two parts Part 1 involves gradually increasing doses to evaluate safety and preliminary antitumor effects, while Part 2 expands the use of the recommended dose from Part 1 to additional participants to continue safety and activity assessments. The study also involves oral administration of Midazolam as part of the treatment evaluation. During the study, participants will be closely monitored for adverse events, laboratory changes, and dose adjustments for up to about two years after treatment. Researchers will assess tumor response using established criteria and collect data on drug concentration and effects over time. Visits will include safety assessments, blood tests, and evaluation of treatment impact, with participation lasting until disease progression, death, or start of new therapy.

CONDITIONS

Brief Title

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Research Team

P

Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here